L E Abrey

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches
    Kathryn Beal
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Radiat Oncol 6:2. 2011
  2. ncbi Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme
    Lauren E Abrey
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Neurol Neurosci Rep 5:167-8. 2005
  3. ncbi Does trastuzumab increase the risk of isolated CNS metastases in patients with breast cancer?
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Neurol 2:302-3. 2006
  4. pmc High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neuro Oncol 8:183-8. 2006
  5. doi Primary central nervous system lymphoma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Curr Opin Neurol 22:675-80. 2009
  6. ncbi Treatment of brain metastases: a short review of current therapies and the emerging role of temozolomide
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Adv Hematol Oncol 1:231-6. 2003
  7. ncbi Treatment-related neurotoxicity
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 19:729-38, viii. 2005
  8. ncbi Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:5034-43. 2005
  9. ncbi Controversies in primary CNS lymphoma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10021, USA
    Expert Rev Neurother 5:459-64. 2005
  10. ncbi High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    J Neurooncol 65:127-34. 2003

Detail Information

Publications91

  1. pmc Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches
    Kathryn Beal
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Radiat Oncol 6:2. 2011
    ..Further research is needed to determine the role of antiangiogenic therapy in frontline treatment and to identify the optimal schedule and partnering agents for use in combination therapy...
  2. ncbi Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme
    Lauren E Abrey
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Neurol Neurosci Rep 5:167-8. 2005
  3. ncbi Does trastuzumab increase the risk of isolated CNS metastases in patients with breast cancer?
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Neurol 2:302-3. 2006
  4. pmc High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neuro Oncol 8:183-8. 2006
    ..This treatment strategy affords long-term disease control to a subset of patients with newly diagnosed anaplastic oligodendroglioma without evidence of delayed neurotoxicity or myelodysplasia...
  5. doi Primary central nervous system lymphoma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Curr Opin Neurol 22:675-80. 2009
    ..This review will summarize recent advances in the understanding and treatment of primary central nervous system lymphoma (PCNSL)...
  6. ncbi Treatment of brain metastases: a short review of current therapies and the emerging role of temozolomide
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Adv Hematol Oncol 1:231-6. 2003
    ..We provide a brief review of current and novel therapies for brain metastases, including new data on the efficacy and safety of temozolomide, a second-generation alkylating agent...
  7. ncbi Treatment-related neurotoxicity
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 19:729-38, viii. 2005
    ..Long-term follow up of prospective therapeutic studies should report on both disease control and the development of neurotoxicity. New protocols should include prospective longitudinal measures of neurocognitive function...
  8. ncbi Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:5034-43. 2005
    ..We hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow us to develop better therapies for patients...
  9. ncbi Controversies in primary CNS lymphoma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10021, USA
    Expert Rev Neurother 5:459-64. 2005
    ..Multiple prospective studies using high-dose methotrexate, with or without whole-brain radiotherapy, have reported improved primary CNS lymphoma outcome, but numerous questions remain regarding the optimal care of a given patient...
  10. ncbi High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    J Neurooncol 65:127-34. 2003
    ....
  11. ncbi Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis
    Lauren E Abrey
    Departments of Neurology and Medicine and the Office of Clinical Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:4151-6. 2003
    ..To assess the safety and efficacy of intensive methotrexate-based chemotherapy followed by high-dose chemotherapy (HDT) with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma (PCNSL)...
  12. ncbi Identifying and addressing barriers to the delivery of optimal therapy for primary central nervous system lymphoma in the broader community
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Leuk Lymphoma 47:2449-52. 2006
    ..We have sought to elaborate some potential causes of these disparities; however, future studies are needed to identify and address specific barriers to care in the community...
  13. ncbi Primary central nervous system lymphoma
    Nimish A Mohile
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Radiat Oncol 17:223-9. 2007
    ..Longer survival, however, is often marred by devastating neurotoxicity to which the elderly are particularly susceptible. Newer regimens aim to minimize such toxicity while maintaining the survival benefit of combined modality treatment...
  14. doi Hematology. Individualized methotrexate dosing in primary CNS lymphoma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Nat Rev Clin Oncol 7:306-7. 2010
    ..The results strongly suggest that effective methotrexate dose is an important variable in patient outcome...
  15. ncbi A phase II trial of temozolomide for patients with recurrent or progressive brain metastases
    L E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Neurooncol 53:259-65. 2001
    ..Treatment options for patients with recurrent brain metastases are extremely limited. This study was designed to determine the safety and efficacy of temozolomide in the treatment of recurrent or progressive brain metastases...
  16. pmc Survey of treatment recommendations for anaplastic oligodendroglioma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neuro Oncol 9:314-8. 2007
    ....
  17. ncbi Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:5711-5. 2006
    ....
  18. ncbi Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial
    A M Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, 10021, USA
    J Neurooncol 78:277-80. 2006
    ..Disease was stable in 6 of 18 patients and the median survival was 27 weeks. This regimen was well tolerated and a phase II trial using a dose of 30 mg/m2 of vinorelbine is warranted...
  19. ncbi Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines
    D D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 18:1145-51. 2007
    ..There is, however, a paucity of research on cognitive functions in this population...
  20. doi A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis
    Nimish A Mohile
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021, USA
    J Neurooncol 89:187-93. 2008
    ....
  21. ncbi Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study
    Rose Lai
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neurology 62:451-6. 2004
    ..Treatment-related leukoencephalopathy is the leading toxicity after successful treatment of primary CNS lymphoma (PCNSL). Its mechanism is poorly understood and there are no autopsy data available on such patients...
  22. ncbi Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma
    J J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Abbott Hall, Room 1123, 710 North Lake Shore Drive, Chicago, IL 60611, USA
    J Neurooncol 71:173-80. 2005
    ..Patients often have complete responses but relapses are common. We characterized the MR spectra of PCNSL patients, correlated MRSI with MRI and evaluated whether early recurrence could be detected by MRSI...
  23. ncbi Treatment for primary CNS lymphoma: the next step
    L E Abrey
    Departments of Neurology and Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 18:3144-50. 2000
    ..The reported protocol was designed to optimize and enhance the chemotherapeutic component of treatment...
  24. ncbi Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma
    Gaurav D Shah
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4730-5. 2007
    ....
  25. doi Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report
    S A Grimm
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neurology 71:1355-60. 2008
    ..To describe the demographics, diagnostic details, therapeutic management, and outcome in patients with primary CNS lymphoma (PCNSL) with ocular involvement...
  26. pmc Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
    F M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Neurology 73:1200-6. 2009
    ..However, patterns of relapse, prognosis, and outcome of further therapy after bevacizumab failure have not been studied systematically...
  27. ncbi Cognitive functions in survivors of primary central nervous system lymphoma
    D D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Neurology 62:548-55. 2004
    ..This combined regimen prolongs patient survival, but also carries a substantial risk for delayed neurotoxicity particularly in the elderly. However, cognitive outcome evaluations have not been included in most clinical trials...
  28. ncbi Temozolomide for treating brain metastases
    L E Abrey
    Department of Neurology at Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 28:34-42. 2001
    ..017), primarily in patients with newly diagnosed brain and lung metastases...
  29. doi Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience
    Douglas E Ney
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 116:4605-12. 2010
    ....
  30. ncbi High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib
    Antonio M P Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 103:2344-8. 2005
    ..Long- term outcome and patterns of disease recurrence after response have not been described...
  31. doi Neurological outcome of long-term glioblastoma survivors
    Andreas F Hottinger
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Neurooncol 95:301-5. 2009
    ..7 years from diagnosis (range: 0.9-11.5 years). Long-term survivors remain rare, but are found across all age groups despite multiple recurrences; clinically significant delayed complications of treatment are common...
  32. ncbi Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up
    Antonio M P Omuro
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Neurology 64:69-74. 2005
    ..To assess the efficacy and safety of a preradiation chemotherapy regimen in patients with primary CNS lymphoma (PCNSL), with emphasis on long-term outcomes...
  33. ncbi Delayed neurotoxicity in primary central nervous system lymphoma
    Antonio M P Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Arch Neurol 62:1595-600. 2005
    ..This delayed neurotoxicity has been poorly defined in the literature, and the underlying mechanisms are unknown...
  34. ncbi Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report
    S A Grimm
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 18:1851-5. 2007
    ..Primary intraocular lymphoma (PIOL) is an uncommon subset of primary central nervous system lymphoma. Because it is rare and difficult to diagnose, the natural history and optimal management are unknown...
  35. doi Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy
    Meltem Ekenel
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 113:1025-31. 2008
    ..Therefore, a retrospective study was conducted to assess the impact of consolidation treatment after a CR to initial induction chemotherapy on disease control and survival...
  36. ncbi Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma
    Andreas F Hottinger
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Neurology 69:1178-82. 2007
    ..Consequently, patients are often treated with chemotherapy alone, and WBRT is deferred until relapse...
  37. pmc A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
    Jeffrey J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Neuro Oncol 12:95-103. 2010
    ..001). Single-agent activity of erlotinib is minimal for recurrent MGs and marginally beneficial following RT for NP GBM patients. Development of rash in cycle 1 correlates with survival in patients with NP GBM after RT...
  38. pmc A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas
    Jeffrey J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Neuro Oncol 12:87-94. 2010
    ..This has important implications for further development of this drug in the treatment of MG as well as the optimal management of patients with other malignancies such as NSCLC who are on enzyme-inducing drugs...
  39. pmc Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma
    Jennifer L Clarke
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY10065, USA
    J Clin Oncol 27:3861-7. 2009
    ..The goal of this randomized phase II study was to evaluate two different temozolomide regimens in the adjuvant treatment of newly diagnosed GBM...
  40. ncbi A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases
    Fabio M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA
    J Neurooncol 87:85-90. 2008
    ..To investigate the efficacy and safety of the combination of vinorelbine and intensive temozolomide for recurrent or progressive brain metastases from solid tumors...
  41. pmc A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
    Raja B Khan
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neuro Oncol 4:39-43. 2002
    ..We conclude that the extended low-dose schedule of temozolomide is well tolerated in heavily pre-treated patients; however, our results do not support an improved rate of response or survival...
  42. doi Prognosis and patterns of care in elderly patients with glioma
    Fabio M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 115:5534-40. 2009
    ..The current study was conducted to evaluate the patterns of care and survival of older adults with oligodendroglioma (OLI) and astrocytoma (AST) from a large population-based registry...
  43. ncbi Update on the therapeutic approaches to brain tumors
    Enrico C Lallana
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Expert Rev Anticancer Ther 3:655-70. 2003
    ..Primary CNS lymphoma, while a relatively rare tumor, is also included as a topic of discussion as the achievements in its treatment represent the principal strides in the evolution of neuro-oncology...
  44. ncbi Brain metastases: old problem, new strategies
    Teri D Nguyen
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 21:369-88. 2007
    ..However, there are several issues specific to brain metastases from breast cancer illustrating that this disease should be considered pathophysiologically distinct, and future research should be tailored accordingly...
  45. doi Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas
    Patrick G Morris
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Target Oncol 5:193-200. 2010
    ..This review describes the preclinical science behind PDGFR and c-KIT, the clinical importance of these molecular pathways and the available data from translational clinical trials...
  46. doi Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy
    Denise D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Neurooncol 91:315-21. 2009
    ..There was no significant cognitive decline up to 24 months post-chemotherapy and reduced-dose WBRT in this group of PCNSL patients, however, difficulties in Verbal Memory and Motor speed persisted over the follow-up period...
  47. pmc Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas
    Philip H Gutin
    Department of Neurosurgery, The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Int J Radiat Oncol Biol Phys 75:156-63. 2009
    ..The objectives of this study were to determine the safety and activity of this combination in malignant gliomas...
  48. doi Therapeutic challenges in primary CNS lymphoma
    Patrick G Morris
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Lancet Neurol 8:581-92. 2009
    ..A promising area of research is the incorporation of novel targeted drugs into standard treatment frameworks. In the future, greater cooperation between research groups should hopefully lead to further therapeutic advances...
  49. ncbi Longitudinal cognitive follow-up in low grade gliomas
    Denise D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Neurooncol 86:321-7. 2008
    ....
  50. ncbi Bcl-6 predicts improved prognosis in primary central nervous system lymphoma
    Oren Levy
    Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, New York, USA
    Cancer 112:151-6. 2008
    ..The objectives of this study were to characterize the immunophenotypes of PCNSL samples and to determine their utility in predicting clinical outcomes...
  51. doi Imaging of lymphoma of the central nervous system, spine, and orbit
    Sofia Haque
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York Presbyterian Hospital Weill Cornell Medical College, New York, NY 10065, USA
    Radiol Clin North Am 46:339-61, ix. 2008
    ..Also described are metabolic imaging techniques with nuclear medicine and advanced MR imaging and how they can help improve the understanding of tumor biology...
  52. ncbi Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas
    Gaurav D Shah
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Neurooncol 85:217-22. 2007
    ..Disease control may also correlate with hematologic toxicity (p = 0.08), suggesting that glioma and marrow stem cells may share a common sensitivity to this chemotherapy regimen...
  53. ncbi Primary central nervous system lymphoma
    Igor T Gavrilovic
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 6:388-95. 2004
    ..Studies looking at oncogenic proteins as potential prognostic markers for PCNSL may help us to develop risk-adapted therapies...
  54. ncbi Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 11:7841-50. 2005
    ....
  55. ncbi Capecitabine therapy of central nervous system metastases from breast cancer
    Meltem Ekenel
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Neurooncol 85:223-7. 2007
    ..Capecitabine may achieve a CR and provide long-term control in patients with both leptomeningeal and parenchymal CNS metastases from breast cancer...
  56. ncbi Cognitive functions in low-grade gliomas: disease and treatment effects
    Denise D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Neurooncol 81:175-84. 2007
    ..The few published studies examining adverse treatment effects on cognition revealed conflicting results...
  57. ncbi Cognitive functions in primary central nervous system lymphoma patients treated with chemotherapy and stem cell transplantation: preliminary findings
    Denise Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Clin Adv Hematol Oncol 1:490. 2003
  58. ncbi Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma
    Igor T Gavrilovic
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:4570-4. 2006
    ..The purpose of this report is to update the initial results and provide long-term data regarding overall survival, patterns of relapse, and the risk of treatment-related neurotoxicity...
  59. ncbi Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
    Raja B Khan
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Neurooncol 58:175-8. 2002
    ..Using a case-controlled retrospective study, matching patients treated with HD-MTX with or without IT-MTX, we found no difference in survival, disease control, or neurotoxicity...
  60. pmc Late relapse in primary central nervous system lymphoma: clonal persistence
    Lakshmi Nayak
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Neuro Oncol 13:525-9. 2011
    ..Long-term persistence of the PCNSL clone was observed in one patient. Patients with late relapses have a good response to salvage therapy and prolonged survival...
  61. ncbi Systemic high-dose intravenous methotrexate for central nervous system metastases
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Neurooncol 78:255-60. 2006
    ..Rapid infusion of high-dose intravenous methotrexate (HD IV MTX) penetrates the blood-brain barrier (BBB) and has reported activity in leptomeningeal metastases...
  62. doi Current management of metastatic brain disease
    Tulika Ranjan
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Neurotherapeutics 6:598-603. 2009
    ..The utility and optimal use of chemotherapy and radiosensitizing agents is less clear. It is hoped that further advances and multidisciplinary approaches currently under study will result in improved patient outcomes...
  63. ncbi New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA
    Clin Cancer Res 11:421-8. 2005
    ..Transport across the BBB relates to the neurovascular unit, which consists not only of endothelial cells but also of pericyte, glia, and neuronal elements...
  64. doi Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997-2007)
    Fabio M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer 115:3758-66. 2009
    ..However, to the authors' knowledge, there is no accepted standard treatment for elderly GBM patients, and specific prognostic factors in the elderly GBM population have not been systematically studied to date...
  65. ncbi Retinopathy in survivors of primary central nervous system lymphoma
    Sean A Grimm
    Memorial Sloan Kettering Cancer Center, Department of Neurology, 1275 York Avenue, New York, NY 10021, USA
    Neurology 67:2060-2. 2006
    ..We describe five patients with long-term primary CNS lymphoma who were diagnosed with retinopathy several years after treatment with chemotherapy and WBRT...
  66. ncbi Diagnosis and treatment of primary central nervous system lymphoma
    Igor T Gavrilovic
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 7:47-54. 2005
    ..Treatment of recurrence also remains controversial. These important questions have prompted several clinical studies looking at novel ways to intensify chemotherapy and limit neurotoxicity...
  67. ncbi Pharmacotherapy of primary CNS lymphoma
    Deric Minwoo Park
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Expert Opin Pharmacother 3:39-49. 2002
    ..Ongoing trials continue to test novel combinations of agents, doses and improved routes of delivery with the hope of improving disease control and diminishing treatment-related neurotoxicity...
  68. ncbi Primary central nervous system lymphoma
    Nimish A Mohile
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Neurol Clin 25:1193-207, xi. 2007
    ..Prolonged survival can be associated with devastating neurotoxicity to which the elderly are particularly susceptible...
  69. ncbi Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road L603, Portland, OR 97201 3098, USA
    Clin Cancer Res 8:1702-9. 2002
    ....
  70. ncbi Patterns of treatment in older adults with primary central nervous system lymphoma
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 110:1338-44. 2007
    ..The objective of the current study was to identify factors associated with the receipt and type of treatment in a population-based cohort of older PCNSL patients...
  71. ncbi Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:2466-72. 2005
    ..The objective of this study was to examine time trends in overall survival and disease-specific mortality in a population-based cohort of patients with PCNSL...
  72. doi Patterns of care in elderly glioblastoma patients
    Fabio M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Neurol 64:628-34. 2008
    ..To evaluate the patterns of care in elderly glioblastoma (GBM) patients from a large population-based registry...
  73. ncbi Leptomeningeal metastases from leukemias and lymphomas
    Craig P Nolan
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 12745 York Avenue, New York, NY 10021, USA
    Cancer Treat Res 125:53-69. 2005
    ..Therefore, aggressive treatment is warranted...
  74. doi Bacterial and fungal meningitis in patients with cancer
    J E Safdieh
    Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, USA
    Neurology 70:943-7. 2008
    ..To analyze cases of bacterial and fungal meningitis in patients with cancer...
  75. ncbi Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide
    Roelien H Enting
    Department of Neurology, University Hospital, Groningen, The Netherlands
    Neurology 63:901-3. 2004
    ..7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL...
  76. ncbi The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma
    Rose Lai
    Department of Epidemiology and Biostatistics, McMaster University Hamilton Regional Cancer Center, Hamilton, Ontario, Canada
    Cancer 101:810-6. 2004
    ..Few studies have compared the risk of central nervous system (CNS) metastases in patients treated with or without trastuzumab...
  77. ncbi Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma
    Warren P Mason
    Department of Medicine, Princess Margaret Hospital, and University of Toronto, Ontario, Canada
    J Neurosurg 97:341-6. 2002
    ..The authors report their experience in using hydroxyurea for the treatment of patients with recurrent or unresectable meningiomas...
  78. ncbi Advancing the treatment of malignant glioma: act local, think global
    Lauren E Abrey
    Cancer Invest 22:169. 2004
  79. pmc Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy
    Jeffrey J Raizer
    Neurology Department, Northwestern Memorial Hospital, Chicago, IL 60611, USA
    Neuro Oncol 6:247-52. 2004
    ..This is the recommended dose for phase 2, but myelosuppression after cycle 1 suggests that long-term treatment may be difficult...
  80. ncbi A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
    Morris D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe, 431, Houston, TX, 77030, USA
    J Neurooncol 81:271-7. 2007
    ..Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)...
  81. ncbi Imaging neurotoxicity: is a picture worth a thousand words?
    Denise D Correa
    AJNR Am J Neuroradiol 26:205-6. 2005
  82. ncbi Chemotherapy for primary central nervous system lymphoma
    Antonio M P Omuro
    Groupe Hospitalier Pitie Salpetriere, Service de Neurologie Mazarin, 47, Boulevard de l Hopital, 75661 Paris Cedex 13, France
    Neurosurg Focus 21:E12. 2006
    ..In this article, the authors discuss the principles guiding the use of chemotherapy for PCNSL, and critically review the available literature, including the most recent trials...
  83. ncbi Chemotherapy and the treatment of brain metastases
    Scott Peak
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 20:1287-95. 2006
    ..The review discusses the biology of brain metastases and provides an update on current chemotherapeutic strategies...
  84. ncbi Salvage temozolomide for prior temozolomide responders
    Enrico Franceschi
    Department of Medical Oncology, Bellaria Hospital, Bologna, Italy
    Cancer 104:2473-6. 2005
    ..In the current study, the authors assessed the outcome and complications of reusing TMZ at the time of disease recurrence in patients who previously responded to treatment...
  85. ncbi Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
    Patrick Y Wen
    Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA
    Clin Cancer Res 12:4899-907. 2006
    ..Phase II: To determine the therapeutic efficacy of imatinib...
  86. ncbi International study on low-grade primary central nervous system lymphoma
    Kristoph Jahnke
    Department of Hematology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Neurol 59:755-62. 2006
    ..The aim of this study was to characterize the clinical presentation, course, and outcome of low-grade primary central nervous system lymphoma...
  87. ncbi Response of glioblastomas to EGFR kinase inhibitors
    Andrew B Lassman
    N Engl J Med 354:525-6; author reply 525-6. 2006
  88. ncbi Chemotherapy for brain metastases: breast, gynecologic and non-melanoma skin malignancies
    Gaurav D Shah
    Memorial Sloan Kettering Cancer Center, Department of Neurology, New York, NY 10021, USA
    Cancer Treat Res 136:185-97. 2007
  89. doi Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma
    Teri N Kreisl
    Neuro Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Leuk Lymphoma 49:1710-6. 2008
    ..028). Despite improved treatment for both diseases over the past decade, survival remains dismal in this cohort of Medicare/Medicaid beneficiaries with HIV-related PCNSL. These results may not apply to the general HIV population...
  90. ncbi Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group
    Tamara N Shenkier
    British Columbia Cancer Agency, 600 W 10th Ave, Vancouver, BC, V5Z 4E6, Canada
    J Clin Oncol 23:2233-9. 2005
    ..To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL)...
  91. pmc CNS Hodgkin lymphoma
    Elizabeth R Gerstner
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Blood 112:1658-61. 2008
    ....